Journal
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 108, Issue 4, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djv363
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [P01 CA87969, P01 CA55075, UM1 CA167552, UM1 CA186107, P50 CA127003, R01 CA136950, R01 CA137178, K24 DK098311, R01 CA151993, R35 CA197735, K07 CA190673]
- Paula and Russell Agrusa Fund for Colorectal Cancer Research
- Friends of the Dana-Farber Cancer Institute
- Entertainment Industry Foundation through National Colorectal Cancer Research Alliance
- Japan Society for the Promotion of Science
- Takashi Tsuruo Memorial Fund
- Harvard University Frank Knox Memorial Fellowship
- Asan Medical Center
- Uehara Memorial Foundation
Ask authors/readers for more resources
Background: Low levels of adiponectin (ADIPOQ; HGNC ID; HGNC: 13633), an adipokine, are associated with obesity, adiposity, excess energy balance, and increased risk of colorectal neoplasia. Given the reported association of increased body mass index (BMI) and low-level physical activity with KRAS-mutated colorectal tumor, we hypothesized that low-level plasma adiponectin might be associated with increased risk of KRAS-mutant colorectal carcinoma but not with risk of KRAS wild-type carcinoma. Methods: We conducted molecular pathological epidemiology research using a nested case-control study design (307 incident rectal and colon cancer case patients and 593 matched control individuals) within prospective cohort studies, the Nurses' Health Study (152 case patients and 297 control individuals, with blood collection in 1989-1990) and the Health Professionals Follow-up Study (155 case patients and 296 control individuals, with blood collection in 1993-1995). Multivariable conditional logistic regression models and two-sided likelihood ratio tests were used to assess etiologic heterogeneity of the associations. Results: The association of low-level plasma adiponectin with colorectal cancer risk statistically significantly differed by KRAS mutation status (P-heterogeneity = .004). Low levels of plasma adiponectin were associated with KRAS-mutant colorectal cancer (for the lowest vs highest tertile: multivariable odds ratio [OR] = 2.83, 95% confidence interval [CI] = 1.50 to 5.34, P-trend = .002) but not with KRAS wild-type cancer (for the lowest vs highest tertile: multivariable OR = 0.83, 95% CI = 0.49 to 1.43, P-trend = .48). In secondary analyses, the association between plasma adiponectin and colorectal cancer did not appreciably differ by BRAF or PIK3CA oncogene mutation status. Conclusions: Low-level plasma adiponectin is associated with KRAS-mutant colorectal cancer risk but not with KRAS wildtype cancer risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available